文献速递免疫规划传染病防控与疫情报告

十价肺炎球菌H流感嗜血杆菌蛋白D结合疫苗对两岁以下儿童呼吸道感染的效果

Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against all respiratory tract infections in children under two years of age.
PubMed 文献 · Vaccine · 2019-04-23

该研究基于芬兰FinIP试验的424名儿童前瞻性队列,比较PHiD-CV10与对照疫苗对两岁以下儿童呼吸道感染的效果。结果显示接种组全因呼吸道感染年率为6.4(95%CI 6.0-6.8),低于对照组的7.4(95%CI 6.8-8.0),疫苗效果为12%(95%CI 2-22%)。

要点

  • PHiD-CV10对两岁以下儿童全因呼吸道感染有12%的疫苗效果。
  • 对伴急性中耳炎的呼吸道感染疫苗效果为23%(95%CI 0-40%)。
  • 对不伴急性中耳炎的呼吸道感染疫苗效果为10%(95%CI 0-19%)。

核心结论

  • 接种PHiD-CV10的儿童两岁以下呼吸道感染发生率低于接种对照疫苗的儿童。

研究设计与样本

  • 研究为前瞻性队列研究(STEPS研究),纳入424名参与FinIP整群随机双盲试验的儿童,于2009-2010年入组,从出生随访至两岁。
  • 儿童按年龄特异性程序接种PHiD-CV10或对照疫苗(甲肝或乙肝疫苗)。

主要发现

  • 368名数据完整的儿童在首剂接种后共记录3193次呼吸道感染事件,多数为上呼吸道感染,由鼻病毒引起。
  • PHiD-CV10接种组全因呼吸道感染年均率为6.4(95%CI 6.0-6.8),对照组为7.4(95%CI 6.8-8.0)。
  • PHiD-CV10接种组伴急性中耳炎的呼吸道感染年均率为1.0(95%CI 0.9-1.2),对照组为1.3(95%CI 1.1-1.6)。
  • 疫苗效果:全因呼吸道感染12%(95%CI 2-22%),伴急性中耳炎的呼吸道感染23%(95%CI 0-40%),不伴急性中耳炎的呼吸道感染10%(95%CI 0-19%)。

关键数值与推荐

  • 疫苗效果估计针对至少接种一剂PHiD-CV10的儿童,调整兄弟姐妹存在和整群随机效应。

临床怎么用

  • 在预防医学与公共卫生实践中,PHiD-CV10接种可考虑用于降低两岁以下儿童呼吸道感染负担。

局限性

  • 研究为前瞻性队列,非完全随机比较,疫苗效果估计可能受混杂因素影响。
  • 样本量有限,部分疫苗效果估计的95%CI下限为0。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pneumococcal conjugate vaccines reduce the incidence of invasive pneumococcal diseases, pneumonia, acute otitis media (AOM), and antimicrobial prescriptions in children. We investigated the effectiveness of at least one dose of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10; GSK) against respiratory tract infections (RTIs) in children under two years of age. METHODS: 424 children enrolled in a cluster-randomized, double-blind Finnish Invasive Pneumococcal disease (FinIP) vaccine trial during the years 2009-2010 were actively followed in a prospective cohort study (STEPS study) for RTIs from birth to two years of age. Children received the PHiD-CV10 vaccine, or a control vaccine (hepatitis A or B vaccine) according to an age-specific schedule. Data on RTIs were collected by symptom diaries, clinic visits, an electronic registry on hospitalizations, and by nasal swab samples analyzed for respiratory viruses. We estimated the vaccine effectiveness against all RTI episodes and RTI episodes with or without AOM by comparing the corresponding incidence rates between PHiD-CV10 vaccinated and control children, adjusted for presence of siblings and cluster as a random effect. RESULTS: A total of 3193 RTI episodes were documented after the first vaccination in 368 children with all data available. The majority of the illnesses were upper RTIs caused by rhinovirus. The PHiD-CV10-vaccinated children had lower mean annual rates of all RTI episodes (6.4; 95% confidence interval [CI], 6.0-6.8) and RTI episodes with AOM (1.0; 95% CI, 0.9-1.2) as compared to the control children (7.4; 95% CI, 6.8-8.0 and 1.3; 95% CI, 1.1-1.6, respectively). The vaccine effectiveness was 12% (95% CI, 2-22%) against all RTIs, 23% (95% CI, 0-40%) against RTIs with AOM, and 10% (95% CI, 0-19%) against RTIs without AOM. CONCLUSIONS: Vaccination with PHiD-CV10 resulted in lower rates of RTIs in children under two years of age compared to children vaccinated with control vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Karppinen S, Toivonen L, Schuez-Havupalo L, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against all respiratory tract infections in children under two years of age. Vaccine. 2019. PMID: 31027929. doi:10.1016/j.vaccine.2019.04.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。